|
2024
|
Invention
|
Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof.
T... |
|
|
Invention
|
Modified double-stranded rna agents.
One aspect of the present invention relates to double-stran... |
|
|
Invention
|
Snca-targeting sirna compositions for treating snca-associated disease.
The disclosure relates t... |
|
|
Invention
|
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof. The present dis... |
|
|
Invention
|
Compositions and methods for silencing carbonic anhydrase 2 expression.
The disclosure relates t... |
|
|
P/S
|
Providing scientific information in the field of biopharmaceuticals. |
|
|
P/S
|
Providing scientific information in the field of
biopharmaceuticals. |
|
|
Invention
|
Aminoadipate-semialdehyde synthase (aass) irna compositions and methods of use thereof. The inven... |
|
|
Invention
|
Methods and compositions for treating ctnnb1-associated disorders. The present invention relates ... |
|
|
Invention
|
Angiotensinogen (agt) irna compositions and methods of use thereof.
The present invention relate... |
|
|
Invention
|
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof.
... |
|
|
P/S
|
Biochemical testing for scientific research purposes. Medical testing for diagnostic or treatment... |
|
|
P/S
|
Scientific research; scientific research in the fields of pharmaceuticals and medicine, chemical ... |
|
|
P/S
|
Scientific research; scientific research in the fields of
pharmaceuticals and medicine, chemical... |
|
|
P/S
|
Scientific research for others in the field of pharmaceutical drug discovery and development; ite... |
|
|
P/S
|
Genetic testing for scientific research purposes. Genetic testing for medical purposes. |
|
|
P/S
|
Scientific research; scientific research in the fields of pharmaceuticals and medicine; chemical ... |
|
|
P/S
|
DNA screening for scientific research purposes; DNA screening for forensic research purposes; DNA... |
|
|
Invention
|
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-a... |
|
|
Invention
|
5'-modified monomers, oligonucleotides and double-stranded rnas. The technology described herein ... |
|
|
Invention
|
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods ... |
|
|
Invention
|
Factor xii (f12) irna compositions and methods of use thereof.
The present invention relates to ... |
|
|
Invention
|
Single-stranded loop oligonucleotides. One aspect of the present invention relates to a single-st... |
|
|
Invention
|
Tunable reversir tm compounds.
The present invention relates, in general to agents that modulate... |
|
|
Invention
|
Extrahepatic delivery.
One aspect of the present invention relates to a double stranded iRNA age... |
|
|
Invention
|
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof.
The present invention re... |
|
|
Invention
|
Mivelsiran compositions and methods of use thereof. The disclosure relates to double stranded rib... |
|
|
Invention
|
Serpina1 irna compositions and methods of use thereof.
The invention relates to RNAi agents, e.g... |
|
|
Invention
|
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof.
The invention relat... |
|
|
Invention
|
Compositions and methods for inhibiting expression of the lect2 gene.
The invention relates to d... |
|
|
P/S
|
Providing scientific information in the field of biopharmaceuticals |
|
|
Invention
|
Huntingtin (htt) irna agent compositions and methods of use thereof.
The disclosure relates to d... |
|
|
Invention
|
Extra-hepatic delivery irna compositions and methods of use thereof.
The present invention provi... |
|
|
Invention
|
Compositions and methods for inhibiting expression of the alas1 gene.
The invention relates to d... |
|
|
Invention
|
Renal injury biomarkers as biomarkers for acute hepatic porphyria (ahp).
The disclosure provides... |
|
|
Invention
|
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof.
The present invention relates... |
|
|
Invention
|
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof.
The present in... |
|
|
Invention
|
Irna compositions and methods for silencing complement component 3 (c3).
The present invention r... |
|
|
Invention
|
Transthyretin (ttr) irna compositions and methods of use thereof.
The present invention relates ... |
|
|
Invention
|
Complement factor b (cfb) irna compositions and methods of use thereof.
The present invention re... |
|
|
Invention
|
Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene ... |
|
|
Invention
|
Oligonucleotide-ligand conjugates and process for their preparation.
The present invention relat... |
|
|
Invention
|
Irna compositions and methods for silencing angiotensinogen (agt).
The present invention relates... |
|
|
Invention
|
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof.
T... |
|
|
Invention
|
Complement component irna compositions and methods of use thereof.
The invention relates to iRNA... |
|
|
Invention
|
Beta-catenin (ctnnb1) irna compositions and methods of use thereof.
The present invention relate... |
|
|
Invention
|
Methods and compositions for treating subjects having or at risk of developing a non-primary hype... |
|
2023
|
Invention
|
Biodegradable lipids for the delivery of active agents.
The present invention relates to a catio... |
|
|
Invention
|
Compositions and methods for inhibiting expression of mutant egfr gene.
The invention relates to... |
|
|
P/S
|
Advertising services to promote public awareness of medical
conditions; advertising services to ... |
|
|
Invention
|
Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof.
The prese... |
|
|
P/S
|
Advertising services to promote public awareness of medical conditions; advertising services to p... |
|
2022
|
Invention
|
Irna compositions and methods for silencing mylip.
The invention relates to double-stranded ribo... |
|
|
Invention
|
Irna compositions and methods for targeting angptl7.
The disclosure relates to double-stranded r... |
|
|
Invention
|
App irna compositions and methods of use thereof for treating or preventing diseases characterize... |
|
|
Invention
|
Peptide ligands for cns and ocular delivery of rnai compounds.
The disclosure relates to RNA age... |
|
|
Invention
|
Simple chemical approaches to introduce 2,6-diaminopurine and 2-aminoadenine conjugates into olig... |
|
|
Invention
|
Integrin targeting ligands for ocular delivery of rnai compounds.
The disclosure relates to RNA ... |
|
|
P/S
|
Providing information on financial assistance programs for the access of pharmaceutical treatment... |
|
2021
|
Invention
|
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs.
This invention relates to a ... |
|
|
P/S
|
Pharmaceuticals having a particularly long duration of
effect as compared to others of the same ... |
|
|
P/S
|
Advertising services to promote public awareness about porphyria among affected individuals and t... |
|
|
P/S
|
Promoting public awareness about porphyria among affected individuals and their families Educatio... |
|
|
P/S
|
Advertising services to promote public awareness about
porphyria among affected individuals and ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of amyloidosis. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of
amyloidosis. |
|
|
P/S
|
Pharmaceutical preparations. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of amyloidosis |
|
|
P/S
|
Promoting public awareness about primary hyperoxaluria among affected individuals and their famil... |
|
|
P/S
|
Maintaining a clinical registry database for patients with inherited disorders of the liver and p... |
|
|
P/S
|
Promoting public awareness about hATTR amyloidosis among affected individuals and their families. |
|
2020
|
P/S
|
Pharmaceutical preparations for the treatment of amyloidosis. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of primary hyperoxaluria. |
|
|
P/S
|
Pharmaceutical preparations for the treatment of transthyretin-mediated amyloidosis; pharmaceutic... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of porphyria. |
